{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T23:04:14Z","timestamp":1792019054526,"version":"4.4.0"},"reference-count":66,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,7,28]],"date-time":"2025-07-28T00:00:00Z","timestamp":1753660800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,7,28]],"date-time":"2025-07-28T00:00:00Z","timestamp":1753660800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cell Death Discov."],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Colorectal cancer is a malignant tumor of the colon or rectum, with approximately 150,000 new cases each year. Current treatment strategies, such as surgery, chemotherapy, radiotherapy, and immunotherapy, face challenges ranging from cancer recurrence, drug resistance to significant toxicity. Therefore, these patients urgently need more effective treatments. Ferroptosis, a novel form of cell death characterized by iron-dependent lipid peroxidation, has emerged as a promising new approach for treating colorectal cancer. Inactivation of phospholipid hydroperoxide glutathione peroxidase (GPX4) or the cysteine\/glutamate antiporter SLC7A11 leads to the depletion of cellular glutathione (GSH), resulting in lipid peroxidation and subsequent ferroptosis. Here, we found that CDH17 and GUCY2C are co-overexpressed in colorectal cancer cells and developed a bispecific antibody-drug conjugate (BsADC) targeting CDH17 and GUCY2C, conjugated with the ferroptosis inducer RSL3 (a GPX4 inhibitor). Experimental results showed that, compared to monoclonal antibody ADCs, BsADC exhibits better binding and internalization activities, and could inhibit tumor cell proliferation more effectively. Moreover, the BsADC displayed an advantageous safety profile in mice. These findings suggest that the CDH17-GUCY2C BsADC, which induces ferroptosis in tumor cells, could be a promising new treatment for colorectal cancer.<\/jats:p>","DOI":"10.1038\/s41420-025-02652-0","type":"journal-article","created":{"date-parts":[[2025,7,28]],"date-time":"2025-07-28T05:16:11Z","timestamp":1753679771000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":17,"title":["Development of a bispecific CDH17-GUCY2C ADC bearing the ferroptosis inducer RSL3 for the treatment of colorectal cancer"],"prefix":"10.1038","volume":"11","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3783-4722","authenticated-orcid":false,"given":"Ying","family":"Zhang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Du","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaohong","family":"Cui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuhang","family":"Ling","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-8154-5383","authenticated-orcid":false,"given":"Chengwu","family":"Tang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,7,28]]},"reference":[{"key":"2652_CR1","first-page":"229","volume":"74","author":"F Bray","year":"2024","unstructured":"Bray F, Laversanne M, Sung H, Ferlay J, Siegel RL, Soerjomataram I, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2024;74:229\u201363.","journal-title":"CA Cancer J Clin"},{"key":"2652_CR2","doi-asserted-by":"publisher","first-page":"669","DOI":"10.1001\/jama.2021.0106","volume":"325","author":"LH Biller","year":"2021","unstructured":"Biller LH, Schrag D. Diagnosis and treatment of metastatic colorectal cancer: a review. JAMA. 2021;325:669\u201385.","journal-title":"JAMA"},{"key":"2652_CR3","doi-asserted-by":"publisher","DOI":"10.1038\/nrdp.2015.65","volume":"1","author":"EJ Kuipers","year":"2015","unstructured":"Kuipers EJ, Grady WM, Lieberman D, Seufferlein T, Sung JJ, Boelens PG, et al. Colorectal cancer. Nat Rev Dis Prim. 2015;1:15065.","journal-title":"Nat Rev Dis Prim"},{"key":"2652_CR4","doi-asserted-by":"publisher","first-page":"294","DOI":"10.1016\/S0140-6736(24)00360-X","volume":"404","author":"C Eng","year":"2024","unstructured":"Eng C, Yoshino T, Ru\u00edz-Garc\u00eda E, Mostafa N, Cann CG, O\u2019Brian B, et al. Colorectal cancer. Lancet. 2024;404:294\u2013310.","journal-title":"Lancet"},{"key":"2652_CR5","first-page":"134","volume":"45","author":"RM Florescu-\u0162enea","year":"2019","unstructured":"Florescu-\u0162enea RM, Kamal AM, Mitru\u0163 P, Mitru\u0163 R, Ilie DS, Nicolaescu AC, et al. Colorectal cancer: an update on treatment options and future perspectives. Curr Health Sci J. 2019;45:134\u201341.","journal-title":"Curr Health Sci J"},{"key":"2652_CR6","doi-asserted-by":"publisher","first-page":"5911","DOI":"10.2147\/CMAR.S186042","volume":"11","author":"F Battaglin","year":"2019","unstructured":"Battaglin F, Puccini A, Ahcene Djaballah S, Lenz HJ. The impact of panitumumab treatment on survival and quality of life in patients with RAS wild-type metastatic colorectal cancer. Cancer Manag Res. 2019;11:5911\u201324.","journal-title":"Cancer Manag Res"},{"key":"2652_CR7","doi-asserted-by":"publisher","unstructured":"Divarasib plus cetuximab is safe and has efficacy in colorectal cancer. Cancer Discov. 2023. https:\/\/doi.org\/10.1158\/2159-8290.CD-RW2023-200.","DOI":"10.1158\/2159-8290.CD-RW2023-200"},{"key":"2652_CR8","doi-asserted-by":"publisher","first-page":"2637","DOI":"10.1200\/JCO.23.02728","volume":"42","author":"C Antoniotti","year":"2024","unstructured":"Antoniotti C, Rossini D, Pietrantonio F, Salvatore L, Lonardi S, Tamberi S, et al. Upfront fluorouracil, leucovorin, oxaliplatin, and irinotecan plus bevacizumab with or without atezolizumab for patients with metastatic colorectal cancer: updated and overall survival results of the ATEZOTRIBE study. J Clin Oncol. 2024;42:2637\u201344.","journal-title":"J Clin Oncol"},{"key":"2652_CR9","first-page":"209","volume":"6","author":"A Kawazoe","year":"2021","unstructured":"Kawazoe A, Ando T, Hosaka H, Fujita J, Koeda K, Nishikawa K, et al. Safety and activity of trifluridine\/tipiracil and ramucirumab in previously treated advanced gastric cancer: an open-label, single-arm, phase 2 trial. Lancet Gastroenterol. 2021;6:209\u201317.","journal-title":"Lancet Gastroenterol"},{"key":"2652_CR10","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-023-38032-4","volume":"14","author":"T Yoshino","year":"2023","unstructured":"Yoshino T, Di Bartolomeo M, Raghav K, Masuishi T, Loupakis F, Kawakami H, et al. Final results of DESTINY-CRC01 investigating trastuzumab deruxtecan in patients with HER2-expressing metastatic colorectal cancer. Nat Commun. 2023;14:3332.","journal-title":"Nat Commun"},{"key":"2652_CR11","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1158\/1541-7786.MCR-19-0582","volume":"18","author":"P Khongorzul","year":"2020","unstructured":"Khongorzul P, Ling CJ, Khan FU, Ihsan AU, Zhang J. Antibody\u2013drug conjugates: a comprehensive review. Mol Cancer Res. 2020;18:3\u201319.","journal-title":"Mol Cancer Res"},{"key":"2652_CR12","doi-asserted-by":"publisher","first-page":"5628","DOI":"10.1002\/jcp.27419","volume":"234","author":"M Abdollahpour-Alitappeh","year":"2019","unstructured":"Abdollahpour-Alitappeh M, Lotfinia M, Gharibi T, Mardaneh J, Farhadihosseinabadi B, Larki P, et al. Antibody-drug conjugates (ADCs) for cancer therapy: Strategies, challenges, and successes. J Cell Physiol. 2019;234:5628\u201342.","journal-title":"J Cell Physiol"},{"key":"2652_CR13","doi-asserted-by":"publisher","DOI":"10.1016\/j.bcp.2024.116101","volume":"223","author":"N Chen","year":"2024","unstructured":"Chen N, He L, Zou Q, Deng H. HER2 targeted therapy in colorectal Cancer: Current landscape and future directions. Biochem Pharmacol. 2024;223:116101.","journal-title":"Biochem Pharmacol"},{"key":"2652_CR14","first-page":"138","volume":"1806","author":"NP Lee","year":"2010","unstructured":"Lee NP, Poon RT, Shek FH, Ng IO, Luk JM. Role of cadherin-17 in oncogenesis and potential therapeutic implications in hepatocellular carcinoma. Biochim Biophys Acta. 2010;1806:138\u201345.","journal-title":"Biochim Biophys Acta"},{"key":"2652_CR15","doi-asserted-by":"publisher","DOI":"10.1186\/s40824-022-00312-3","volume":"26","author":"J Ma","year":"2022","unstructured":"Ma J, Xu X, Fu C, Xia P, Tian M, Zheng L, et al. CDH17 nanobodies facilitate rapid imaging of gastric cancer and efficient delivery of immunotoxin. Biomater Res. 2022;26:64.","journal-title":"Biomater Res"},{"key":"2652_CR16","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1158\/1535-7163.MCT-20-0253","volume":"20","author":"JM Garc\u00eda-Mart\u00ednez","year":"2021","unstructured":"Garc\u00eda-Mart\u00ednez JM, Wang S, Weishaeupl C, Wernitznig A, Chetta P, Pinto C, et al. Selective tumor cell apoptosis and tumor regression in CDH17-positive colorectal cancer models using BI 905711, a novel liver-sparing TRAILR2 agonist. Mol Cancer Ther. 2021;20:96\u2013108.","journal-title":"Mol Cancer Ther"},{"key":"2652_CR17","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1016\/j.canlet.2019.04.022","volume":"454","author":"X Liu","year":"2019","unstructured":"Liu X, Huang Y, Yuan H, Qi X, Manjunath Y, Avella D, et al. Disruption of oncogenic liver-intestine cadherin (CDH17) drives apoptotic pancreatic cancer death. Cancer Lett. 2019;454:204\u201314.","journal-title":"Cancer Lett"},{"key":"2652_CR18","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1200\/JGO.2019.5.suppl.53","volume":"5","author":"H Tsoi","year":"2019","unstructured":"Tsoi H, Wong K-F, Luk JM, Staunton D. Clinical utility of CDH17 biomarker in tumor tissues and liquid biopsies for detection and prognostic staging of colorectal cancer (CRC). J Glob Oncol. 2019;5:53\u201353.","journal-title":"J Glob Oncol"},{"key":"2652_CR19","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1309\/AJCPKSHXI3XEHW1J","volume":"138","author":"NC Panarelli","year":"2012","unstructured":"Panarelli NC, Yantiss RK, Yeh MM, Liu Y, Chen YT. Tissue-specific cadherin CDH17 is a useful marker of gastrointestinal adenocarcinomas with higher sensitivity than CDX2. Am J Clin Pathol. 2012;138:211\u201322.","journal-title":"Am J Clin Pathol"},{"key":"2652_CR20","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1007\/s00408-023-00648-0","volume":"201","author":"W Tian","year":"2023","unstructured":"Tian W, Zhao J, Wang W. Targeting CDH17 with chimeric antigen receptor-redirected T cells in small cell lung cancer. Lung. 2023;201:489\u201397.","journal-title":"Lung"},{"key":"2652_CR21","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1016\/j.tem.2013.01.001","volume":"24","author":"GW Kim","year":"2013","unstructured":"Kim GW, Lin JE, Waldman SA. GUCY2C: at the intersection of obesity and cancer. Trends Endocrinol Metab. 2013;24:165\u201373.","journal-title":"Trends Endocrinol Metab"},{"key":"2652_CR22","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1080\/23808993.2021.1876518","volume":"6","author":"AN Lisby","year":"2021","unstructured":"Lisby AN, Flickinger JC Jr, Bashir B, Weindorfer M, Shelukar S, et al. GUCY2C as a biomarker to target precision therapies for patients with colorectal cancer. Expert Rev Precis Med Drug Dev. 2021;6:117\u201329.","journal-title":"Expert Rev Precis Med Drug Dev"},{"key":"2652_CR23","doi-asserted-by":"publisher","first-page":"e1227897","DOI":"10.1080\/2162402X.2016.1227897","volume":"5","author":"MS Magee","year":"2016","unstructured":"Magee MS, Kraft CL, Abraham TS, Baybutt TR, Marszalowicz GP, Li P, et al. GUCY2C-directed CAR-T cells oppose colorectal cancer metastases without autoimmunity. Oncoimmunology. 2016;5:e1227897.","journal-title":"Oncoimmunology"},{"key":"2652_CR24","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1038\/s41580-020-00324-8","volume":"22","author":"X Jiang","year":"2021","unstructured":"Jiang X, Stockwell BR, Conrad M. Ferroptosis: mechanisms, biology and role in disease. Nat Rev Mol Cell Biol. 2021;22:266\u201382.","journal-title":"Nat Rev Mol Cell Biol"},{"key":"2652_CR25","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2022.113524","volume":"153","author":"Y Wang","year":"2022","unstructured":"Wang Y, Zhang Z, Sun W, Zhang J, Xu Q, Zhou X, et al. Ferroptosis in colorectal cancer: Potential mechanisms and effective therapeutic targets. Biomed Pharmacother. 2022;153:113524.","journal-title":"Biomed Pharmacother"},{"key":"2652_CR26","doi-asserted-by":"publisher","first-page":"1439","DOI":"10.1038\/s41416-023-02149-6","volume":"128","author":"H Yan","year":"2023","unstructured":"Yan H, Talty R, Aladelokun O, Bosenberg M, Johnson CH. Ferroptosis in colorectal cancer: a future target? Br J Cancer. 2023;128:1439\u201351.","journal-title":"Br J Cancer"},{"key":"2652_CR27","doi-asserted-by":"publisher","DOI":"10.1186\/s12935-021-02366-0","volume":"22","author":"Q Nie","year":"2022","unstructured":"Nie Q, Hu Y, Yu X, Li X, Fang X. Induction and application of ferroptosis in cancer therapy. Cancer Cell Int. 2022;22:12.","journal-title":"Cancer Cell Int"},{"key":"2652_CR28","doi-asserted-by":"publisher","first-page":"1071","DOI":"10.1002\/cac2.12487","volume":"43","author":"Y Zheng","year":"2023","unstructured":"Zheng Y, Sun L, Guo J, Ma J. The crosstalk between ferroptosis and anti-tumor immunity in the tumor microenvironment: molecular mechanisms and therapeutic controversy. Cancer Commun (Lond). 2023;43:1071\u201396.","journal-title":"Cancer Commun (Lond)"},{"key":"2652_CR29","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1016\/j.ccell.2024.03.011","volume":"42","author":"G Lei","year":"2024","unstructured":"Lei G, Zhuang L, Gan B. The roles of ferroptosis in cancer: Tumor suppression, tumor microenvironment, and therapeutic interventions. Cancer Cell. 2024;42:513\u201334.","journal-title":"Cancer Cell"},{"key":"2652_CR30","doi-asserted-by":"publisher","first-page":"1371","DOI":"10.3389\/fphar.2018.01371","volume":"9","author":"X Sui","year":"2018","unstructured":"Sui X, Zhang R, Liu S, Duan T, Zhai L, Zhang M, et al. RSL3 drives ferroptosis through GPX4 inactivation and ROS production in colorectal cancer. Front Pharmacol. 2018;9:1371.","journal-title":"Front Pharmacol"},{"key":"2652_CR31","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1186\/s13046-024-03032-9","volume":"43","author":"Y Qiao","year":"2024","unstructured":"Qiao Y, Su M, Zhao H, Liu H, Wang C, Dai X, et al. Targeting FTO induces colorectal cancer ferroptotic cell death by decreasing SLC7A11\/GPX4 expression. J Exp Clin Cancer Res. 2024;43:108.","journal-title":"J Exp Clin Cancer Res"},{"key":"2652_CR32","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejmech.2022.114863","volume":"244","author":"KA Nguyen","year":"2022","unstructured":"Nguyen KA, Conilh L, Falson P, Dumontet C, Boumendjel A. The first ADC bearing the ferroptosis inducer RSL3 as a payload with conservation of the fragile electrophilic warhead. Eur J Med Chem. 2022;244:114863.","journal-title":"Eur J Med Chem"},{"key":"2652_CR33","doi-asserted-by":"publisher","first-page":"2710","DOI":"10.1158\/0008-5472.CAN-15-1795","volume":"76","author":"F Li","year":"2016","unstructured":"Li F, Emmerton KK, Jonas M, Zhang X, Miyamoto JB, Setter JR, et al. Intracellular released payload influences potency and bystander-killing effects of antibody-drug conjugates in preclinical models. Cancer Res. 2016;76:2710\u20139.","journal-title":"Cancer Res"},{"key":"2652_CR34","doi-asserted-by":"publisher","first-page":"1537","DOI":"10.1158\/1535-7163.MCT-13-0926","volume":"13","author":"S Golfier","year":"2014","unstructured":"Golfier S, Kopitz C, Kahnert A, Heisler I, Schatz CA, Stelte-Ludwig B, et al. Anetumab ravtansine: a novel mesothelin-targeting antibody-drug conjugate cures tumors with heterogeneous target expression favored by bystander effect. Mol Cancer Ther. 2014;13:1537\u201348.","journal-title":"Mol Cancer Ther"},{"key":"2652_CR35","first-page":"12","volume":"74","author":"RL Siegel","year":"2024","unstructured":"Siegel RL, Giaquinto AN, Jemal A. Cancer statistics, 2024. CA Cancer J Clin. 2024;74:12\u201349.","journal-title":"CA Cancer J Clin"},{"key":"2652_CR36","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1016\/j.tips.2023.01.003","volume":"44","author":"AE Shin","year":"2023","unstructured":"Shin AE, Giancotti FG, Rustgi AK. Metastatic colorectal cancer: mechanisms and emerging therapeutics. Trends Pharm Sci. 2023;44:222\u201336.","journal-title":"Trends Pharm Sci"},{"key":"2652_CR37","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-024-02119-3","volume":"23","author":"M Tufail","year":"2024","unstructured":"Tufail M, Jiang C-H, Li N. Altered metabolism in cancer: insights into energy pathways and therapeutic targets. Mol Cancer. 2024;23:203.","journal-title":"Mol Cancer"},{"key":"2652_CR38","doi-asserted-by":"publisher","DOI":"10.1038\/s41419-020-2298-2","volume":"11","author":"J Li","year":"2020","unstructured":"Li J, Cao F, Yin HL, Huang ZJ, Lin ZT, Mao N, et al. Ferroptosis: past, present and future. Cell Death Dis. 2020;11:88.","journal-title":"Cell Death Dis"},{"key":"2652_CR39","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1056\/NEJMoa2212419","volume":"388","author":"R Yaeger","year":"2023","unstructured":"Yaeger R, Weiss J, Pelster MS, Spira AI, Barve M, Ou SI, et al. Adagrasib with or without cetuximab in colorectal cancer with mutated KRAS G12C. N Engl J Med. 2023;388:44\u201354.","journal-title":"N Engl J Med"},{"key":"2652_CR40","doi-asserted-by":"publisher","DOI":"10.1038\/s41419-021-04367-3","volume":"12","author":"J Yang","year":"2021","unstructured":"Yang J, Mo J, Dai J, Ye C, Cen W, Zheng X, et al. Cetuximab promotes RSL3-induced ferroptosis by suppressing the Nrf2\/HO-1 signalling pathway in KRAS mutant colorectal cancer. Cell Death Dis. 2021;12:1079.","journal-title":"Cell Death Dis"},{"key":"2652_CR41","doi-asserted-by":"publisher","first-page":"5107","DOI":"10.7150\/thno.44705","volume":"10","author":"P Chen","year":"2020","unstructured":"Chen P, Li X, Zhang R, Liu S, Xiang Y, Zhang M, et al. Combinative treatment of \u03b2-elemene and cetuximab is sensitive to KRAS mutant colorectal cancer cells by inducing ferroptosis and inhibiting epithelial-mesenchymal transformation. Theranostics. 2020;10:5107\u201319.","journal-title":"Theranostics"},{"key":"2652_CR42","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1038\/s41420-022-01297-7","volume":"8","author":"Y Du","year":"2022","unstructured":"Du Y, Guo Z. Recent progress in ferroptosis: inducers and inhibitors. Cell Death Discov. 2022;8:501.","journal-title":"Cell Death Discov"},{"key":"2652_CR43","doi-asserted-by":"publisher","DOI":"10.1016\/j.canlet.2022.215969","volume":"552","author":"Y Yang","year":"2023","unstructured":"Yang Y, Wang S, Ma P, Jiang Y, Cheng K, Yu Y, et al. Drug conjugate-based anticancer therapy - Current status and perspectives. Cancer Lett. 2023;552:215969.","journal-title":"Cancer Lett"},{"key":"2652_CR44","doi-asserted-by":"publisher","DOI":"10.1002\/mco2.671","volume":"5","author":"J He","year":"2024","unstructured":"He J, Zeng X, Wang C, Wang E, Li Y. Antibody-drug conjugates in cancer therapy: mechanisms and clinical studies. MedComm (2020). 2024;5:e671.","journal-title":"MedComm (2020)"},{"key":"2652_CR45","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.jconrel.2021.10.006","volume":"340","author":"D Singh","year":"2021","unstructured":"Singh D, Dheer D, Samykutty A, Shankar R. Antibody drug conjugates in gastrointestinal cancer: From lab to clinical development. J Control Release. 2021;340:1\u201334.","journal-title":"J Control Release"},{"key":"2652_CR46","doi-asserted-by":"publisher","first-page":"1675613","DOI":"10.1155\/2020\/6901472","volume":"2020","author":"L Zhang","year":"2020","unstructured":"Zhang L, Liu W, Liu F, Wang Q, Song M, Yu Q, et al. IMCA Induces Ferroptosis Mediated by SLC7A11 through the AMPK\/mTOR Pathway in Colorectal Cancer. Oxid Med Cell Longev. 2020;2020:1675613.","journal-title":"Oxid Med Cell Longev"},{"key":"2652_CR47","doi-asserted-by":"publisher","first-page":"2334","DOI":"10.1002\/cbin.11443","volume":"44","author":"D Lu","year":"2020","unstructured":"Lu D, Yang Z, Xia Q, Gao S, Sun S, Luo X, et al. ACADSB regulates ferroptosis and affects the migration, invasion, and proliferation of colorectal cancer cells. Cell Biol Int. 2020;44:2334\u201343.","journal-title":"Cell Biol Int"},{"key":"2652_CR48","doi-asserted-by":"publisher","first-page":"1333","DOI":"10.2147\/CMAR.S274631","volume":"13","author":"X Tian","year":"2021","unstructured":"Tian X, Li S, Ge G. Apatinib promotes ferroptosis in colorectal cancer cells by targeting ELOVL6\/ACSL4 signaling. Cancer Manag Res. 2021;13:1333\u201342.","journal-title":"Cancer Manag Res"},{"key":"2652_CR49","doi-asserted-by":"publisher","DOI":"10.1038\/s41419-024-06572-2","volume":"15","author":"H Liu","year":"2024","unstructured":"Liu H, Zhou D, Liu D, Xu X, Zhang K, Hu R, et al. Synergistic antitumor activity between HER2 antibody-drug conjugate and chemotherapy for treating advanced colorectal cancer. Cell Death Dis. 2024;15:187.","journal-title":"Cell Death Dis"},{"key":"2652_CR50","doi-asserted-by":"publisher","first-page":"159","DOI":"10.2217\/bmm.12.90","volume":"7","author":"T Hyslop","year":"2013","unstructured":"Hyslop T, Waldman SA. Guanylyl cyclase C as a biomarker in colorectal cancer. Biomark Med. 2013;7:159\u201367.","journal-title":"Biomark Med"},{"key":"2652_CR51","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1200\/JCO.2023.41.4_suppl.245","volume":"41","author":"M Malla","year":"2023","unstructured":"Malla M, Deshmukh SK, Wu S, Xiu J, Farrell AP, Lenz H-J, et al. Comprehensive characterization of mesothelin expression in colorectal cancer. J Clin Oncol. 2023;41:245\u2013245.","journal-title":"J Clin Oncol"},{"key":"2652_CR52","doi-asserted-by":"publisher","first-page":"2362","DOI":"10.1158\/1538-7445.AM2024-2362","volume":"84","author":"S Raab-Westphal","year":"2024","unstructured":"Raab-Westphal S, Hart F, Sloot W, Shan M, Rasche N, Amendt C, et al. Abstract 2362: Preclinical efficacy and safety of M9140, a novel antibody-drug conjugate (ADC) with topoisomerase 1 (TOP1) inhibitor payload targeting carcinoembryonic antigen-related cell adhesion molecule 5 (CEACAM5)-expressing colorectal tumors. Cancer Res. 2024;84:2362\u20132362.","journal-title":"Cancer Res"},{"key":"2652_CR53","first-page":"1592","volume":"128","author":"J Jacob","year":"2023","unstructured":"Jacob J, Francisco LE, Chatterjee T, Liang Z, Subramanian S, Liu QJ, et al. An antibody\u2013drug conjugate targeting GPR56 demonstrates efficacy in preclinical models of colorectal cancer. Br J Cancer. 2023;128:1592\u2013602.","journal-title":"Br J Cancer"},{"key":"2652_CR54","doi-asserted-by":"publisher","first-page":"1965","DOI":"10.1016\/j.apsb.2024.01.009","volume":"14","author":"Y Gu","year":"2024","unstructured":"Gu Y, Wang Z, Wang Y. Bispecific antibody drug conjugates: Making 1+1>2. Acta Pharm Sin B. 2024;14:1965\u201386.","journal-title":"Acta Pharm Sin B"},{"key":"2652_CR55","doi-asserted-by":"publisher","first-page":"350","DOI":"10.1126\/science.aag3267","volume":"354","author":"AZ Wec","year":"2016","unstructured":"Wec AZ, Nyakatura EK, Herbert AS, Howell KA, Holtsberg FW, Bakken RR, et al. A \u201cTrojan horse\u201d bispecific-antibody strategy for broad protection against ebolaviruses. Science. 2016;354:350\u20134.","journal-title":"Science"},{"key":"2652_CR56","doi-asserted-by":"publisher","first-page":"339","DOI":"10.4161\/mabs.1.4.8755","volume":"1","author":"C Wu","year":"2009","unstructured":"Wu C, Ying H, Bose S, Miller R, Medina L, Santora L, et al. Molecular construction and optimization of anti-human IL-1alpha\/beta dual variable domain immunoglobulin (DVD-Ig) molecules. MAbs. 2009;1:339\u201347.","journal-title":"MAbs"},{"key":"2652_CR57","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1038\/s41573-019-0028-1","volume":"18","author":"AF Labrijn","year":"2019","unstructured":"Labrijn AF, Janmaat ML, Reichert JM, Parren P. Bispecific antibodies: a mechanistic review of the pipeline. Nat Rev Drug Discov. 2019;18:585\u2013608.","journal-title":"Nat Rev Drug Discov"},{"key":"2652_CR58","doi-asserted-by":"publisher","DOI":"10.1080\/19420862.2023.2180794","volume":"15","author":"X Pang","year":"2023","unstructured":"Pang X, Huang Z, Zhong T, Zhang P, Wang ZM, Xia M, et al. Cadonilimab, a tetravalent PD-1\/CTLA-4 bispecific antibody with trans-binding and enhanced target binding avidity. MAbs. 2023;15:2180794.","journal-title":"MAbs"},{"key":"2652_CR59","doi-asserted-by":"publisher","first-page":"901","DOI":"10.1016\/S1470-2045(24)00159-1","volume":"25","author":"Y Ma","year":"2024","unstructured":"Ma Y, Huang Y, Zhao Y, Zhao S, Xue J, Yang Y, et al. BL-B01D1, a first-in-class EGFR-HER3 bispecific antibody-drug conjugate, in patients with locally advanced or metastatic solid tumours: a first-in-human, open-label, multicentre, phase 1 study. Lancet Oncol. 2024;25:901\u201311.","journal-title":"Lancet Oncol"},{"key":"2652_CR60","doi-asserted-by":"publisher","first-page":"901","DOI":"10.1016\/S1470-2045(24)00159-1","volume":"25","author":"Y Ma","year":"2024","unstructured":"Ma Y, Huang Y, Zhao Y, Zhao S, Xue J, Yang Y, et al. BL-B01D1, a first-in-class EGFR\u2013HER3 bispecific antibody\u2013drug conjugate, in patients with locally advanced or metastatic solid tumours: a first-in-human, open-label, multicentre, phase 1 study. Lancet Oncol. 2024;25:901\u201311.","journal-title":"Lancet Oncol"},{"key":"2652_CR61","doi-asserted-by":"publisher","first-page":"LB043","DOI":"10.1158\/1538-7445.AM2024-LB043","volume":"84","author":"W Wang","year":"2024","unstructured":"Wang W, Li J, Ma L, Xu M, Yin Q. Abstract LB043: VBC101-F11: An innovative EGFR\/cMet bispecific antibody drug conjugate (ADC) targeting key oncogenic drivers in solid tumors. Cancer Res. 2024;84:LB043\u2013LB043.","journal-title":"Cancer Res"},{"key":"2652_CR62","first-page":"A1168","volume":"12","author":"S Gong","year":"2024","unstructured":"Gong S, Zhang R, Li B, Mao J, Zhang N, Zhang Y, et al. 1048 A differentiated cMet x EGFR bispecific antibody-drug conjugate demonstrated broad antitumor activity and promising safety profile in preclinical models. J Immuno Ther Cancer. 2024;12:A1168\u2013A1168.","journal-title":"J Immuno Ther Cancer"},{"key":"2652_CR63","doi-asserted-by":"publisher","first-page":"S39","DOI":"10.1016\/j.annonc.2022.02.031","volume":"33","author":"Z Qing","year":"2022","unstructured":"Qing Z, Gabrail N, Uprety D, Rotow J, Han B, J\u00e4nne PA, et al. 22P EMB-01: An EGFR-cMET bispecific antibody, in advanced\/metastatic solid tumors phase I results. Ann Oncol. 2022;33:S39\u2013S40.","journal-title":"Ann Oncol"},{"key":"2652_CR64","doi-asserted-by":"publisher","first-page":"2655","DOI":"10.1182\/blood.2020010477","volume":"138","author":"C Augsberger","year":"2021","unstructured":"Augsberger C, H\u00e4nel G, Xu W, Pulko V, Hanisch LJ, Augustin A, et al. Targeting intracellular WT1 in AML with a novel RMF-peptide-MHC-specific T-cell bispecific antibody. Blood. 2021;138:2655\u201369.","journal-title":"Blood"},{"key":"2652_CR65","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1016\/j.ymeth.2018.10.001","volume":"154","author":"L Han","year":"2019","unstructured":"Han L, Zong H, Zhou Y, Pan Z, Chen J, Ding K, et al. Naturally split intein Npu DnaE mediated rapid generation of bispecific IgG antibodies. Methods. 2019;154:32\u201337.","journal-title":"Methods"},{"key":"2652_CR66","doi-asserted-by":"publisher","first-page":"1158","DOI":"10.1016\/j.biotechadv.2011.08.022","volume":"30","author":"J Zhu","year":"2012","unstructured":"Zhu J. Mammalian cell protein expression for biopharmaceutical production. Biotechnol Adv. 2012;30:1158\u201370.","journal-title":"Biotechnol Adv"}],"container-title":["Cell Death Discovery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41420-025-02652-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41420-025-02652-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41420-025-02652-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,8]],"date-time":"2025-09-08T04:47:40Z","timestamp":1757306860000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41420-025-02652-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,28]]},"references-count":66,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["2652"],"URL":"https:\/\/doi.org\/10.1038\/s41420-025-02652-0","relation":{},"ISSN":["2058-7716"],"issn-type":[{"value":"2058-7716","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,28]]},"assertion":[{"value":"25 January 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 June 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 July 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 July 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"The research was approved by the Institutional Animal Care and Use Committee of the Institute of First Affiliated Hospital of Huzhou University.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics"}},{"value":"We have obtained consent from all participants in this study to publish this paper.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}}],"article-number":"347"}}